ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1450

Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-based Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 0281

Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis
Abstract Number: 0211

Unsupervised Machine-learning Algorithms for the Identification of Clinical Phenotypes in the Osteoarthritis Initiative Database
Abstract Number: 1848

Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis
Abstract Number: 1855

Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis
Abstract Number: 1340

Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)
Abstract Number: 0549

Upregulation of Prostanoid EP2 Receptors and Meditation of Treprostinil Anti-Proliferative Effects in Scleroderma Smooth Muscle Cells
Abstract Number: 1575

Urate Crystals Regulate a Distinct JNK-Dependent Metabolic and Inflammatory Response
Abstract Number: 1900

Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
Abstract Number: 0675

Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Abstract Number: 1422

Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach
Abstract Number: 0340

Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Abstract Number: 0331

Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
Abstract Number: 0423

Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Abstract Number: 0701

Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].